http://www.igenericdrugs.com Review Rating: 100 out of 100 based on 1298 reviews. 1298 stars
Generic drugs
List of interchangeable brand and generic drugs
compare generic drug prices
 

Paclitaxel Cipla

Choose a suitable interchangeable generic or brand drug, if you could not find the prescribed medicine.
We do not sell drugs. This site contains prices only for information purposes to help you buy drugs cheaply.
You should consult a doctor about the dosage before using this medicine!

DRUG NAME:     

 

Paclitaxel Cipla uses and description

Sort by popularity
Paclitaxel Cipla - Paclitaxel Cipla is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the body.

Paclitaxel Cipla is used to treat breast cancer, lung cancer, and ovarian cancer. It is also used to treat AIDS-related Kaposi's sarcoma.

Paclitaxel Cipla may also be used for other purposes not listed in this medication guide.

Pharmacology: Paclitaxel Cipla is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability inhibits the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, Paclitaxel Cipla induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis, further disrupting cell function.

Indication: For the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 mo of adjuvant chemotherapy (prior therapy should have included an anthracycline unless clinically contraindicated); treatment of advanced carcinoma of the ovary ( Onxol only).

Unlabeled Uses

Squamous cell head and neck cancer, small-cell lung cancer, bladder cancer, esophageal cancer, testicular cancer, endometrial cancer, prostate cancer, gastric cancer, germ cell tumors, refractory leukemia, and recurrent Wilms tumor in children.

Paclitaxel Cipla is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel Cipla is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, Paclitaxel Cipla induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

Intravenous Ovarian carcinoma

Adult: Primary treatment (in combination with cisplatin or carboplatin): 135 mg/m 2 infused over 24 hr followed by cisplatin and repeated at 3 wk intervals. Secondary treatment (as single agent): 135 or 175 mg/m 2 infused over 3 hr once every 3 wk. Hepatic impairment: Do not use in severe impairment, increased risk of hepatotoxicity. For detailed dosing recommendations, consult local protocol. Intravenous Breast cancer

Adult: Adjuvant therapy; 2nd line monotherapy or 1st line treatment with trastuzumab: 175 mg/m 2 infused over 3 hr once every 3 wk for 4 courses; when used with trastuzumab, dose should be given the day after the 1st dose of trastuzumab or immediately after subsequent doses if well-tolerated. 1st line with doxorubicin: 220 mg/m 2 over 3 hr every 3 wk, dose to be administered 24 hr after doxorubicin. Hepatic impairment: Do not use in severe impairment, increased risk of hepatotoxicity. For detailed dosing recommendation, consult local protocol. Intravenous Advanced non-small cell lung cancer

Adult: 135 mg/m 2 over 24 hr or 175 mg/m 2 over 3 hr, followed by cisplatin and repeated at 3 wk intervals. Hepatic impairment: Do not use in severe impairment, increased risk of hepatotoxicity. For detailed dosing recommendation, consult local protocol. Intravenous AIDS-related Kaposi's sarcoma

Adult: 135 mg/m 2 over 3 hr every 3 wk. Alternatively, 100 mg/m 2 over 3 hr every 2 wk especially in patients with poor performance status. Hepatic impairment: Do not use in severe impairment, increased risk of hepatotoxicity. For detailed dosing recommendation, consult local protocol. Reconstitution: Paclitaxel Cipla must be diluted before infusion. It can be diluted in 0.9% sodium chloride inj, 5% dextrose inj, 5% dextrose and 0.9% sodium chloride inj or 5% dextrose in lactated Ringer's inj to a concentration of 0.3-1.2 mg/ml. Incompatibility: Do not prepare, store or administer in PVC containing equipment; macrogol glycerol ricinolate (an excipient) can cause [di-(2-ethylhexyl)phthalate] (DEHP) leaching. Y-site incompatibility: Amphotericin B, amphotericin B cholesteryl sulfate complex, chlorpromazine, doxorubicin liposome, hydroxyzine, methylprednisolone sodium succinate, mitoxantrone. Variable compatibility when admixed with cisplatin.

Indications:

Adult: IV Ovarian carcinoma Primary treatment: 135 mg/m 2, followed by cisplatin. Repeat 3 wkly. Secondary treatment: As single agent: 135 or 175 mg/m 2 3 wkly. Breast cancer As adjunct therapy, 2nd line monotherapy or 1st line treatment w/ trastuzumab: 175 mg/m 2 3 wkly for 4 courses. W/ trastuzumub, give dose one day after 1st dose of trastuzumab or immediately after subsequent doses if tolerated. 1st line treatment w/ doxorubicin: 220 mg/m 2 3 wkly, give dose 24 hr after doxurubicin. Advanced non-small cell lung cancer 135 mg/m 2 over 24 hr, followed by cisplatin. Repeat 3 wkly. AIDS-related Kaposi's sarcoma 135 mg/m 2 3 wkly.

Active ingredients: Paclitaxel
Unit description, dosagePrice, USD

List of paclitaxel cipla brand and generic drugs

Paclitaxel-Teva (Czech Republic, Estonia, France, Hungary, Italy, Latvia, Lithuania, Slovakia, Spain, Sweden, Switzerland)
Paclitaxel-Teva 6 mg/1 mL x 25 mL
Paclitaxelum Actavis (Vietnam)
Paclitaxelum Actavis 30 mg x 1 loï
Paclitaxelum Actavis 100 mg x 1 loï
Paclitaxelum Actavis 150 mg x 1 loï
Paclitaxelum Actavis 260 mg x 1 loï
Paclitaxelum Actavis 300 mg x 1 loï
Paclitaxin (Taiwan)
Paclitaxin 6 mg/1 mL x 5 mL
Paclitaxin 6 mg/1 mL x 16.7 mL
Paclitaxin 6 mg/1 mL x 25 mL
Paclitaxin 6 mg/1 mL x 50 mL
Paclitaxin 30 mg/5 mL x 1's
Paclitaxin 100 mg/16.7 mL x 1's$ 381.25
Paclitaxin 300 mg/50 mL x 1's$ 562.50
Paclitaxin (vial) 30 mg/5 mL x 1's$ 112.50
Paclitaxin Concentrate (Singapore)
Paclitaxin Concentrate 6 mg/1 mL x 1's
Paclitec (India)
Paclitec 30mg x 5mL VIAL / 1
Paclitec 100mg x 20mL VIAL / 1
Paclitec 260mg x 43.4mL VIAL / 1
30 mg x 5 mL x 1's
100 mg x 20 mL x 1's
260 mg x 43.4 mL x 1's
Paclitera
Injectable; Injection; Paclitaxel 6 mg / ml
Pacliteva (Argentina)
Paclitol (Greece)
PACLITRUST (India)
30 mg x 1's$ 27.78
100 mg x 1's$ 70.37
300 mg x 1's$ 166.67
Paclitrust 30mg VIAL / 1$ 27.78
Paclitrust 100mg VIAL / 1$ 70.37
Paclitrust 300mg VIAL / 1$ 166.67
Paclixel (Greece)
Pacovary (Latvia, Lithuania)
Pactal (Philippines)
Pactal (vial) 6 mg/1 mL x 5 mL x 1's
Pactal 6 mg/1 mL x 16.7 mL x 1's
Pactal 6 mg/1 mL x 25 mL x 1's
Pactal 6 mg/1 mL x 43.33 mL x 1's
Pactal 6 mg/1 mL x 50 mL x 1's
Padexol (Vietnam)
Padexol 6 mg/1 mL x 1 loï 5 mL
Padexol 6 mg/1 mL x 1 loï 16.67 mL
Padexol 6 mg/1 mL x 1 loï 33.34 mL
Padexol 6 mg/1 mL x 1 loï 50 mL
Paklitaksel Mylan (Slovenia)

Show all Paclitaxel Cipla generic names
 
Privacy Policy
© 2003 - 2014 igenericdrugs.com All Rights Reserved
 
Disclamer